drugset / Trial / NCT03718143
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase II study testing the efficacy of combined AZD1775 with AraC or single agent activity of AZD1775 in three arms: Arm A has subjects age 60 years or older who are newly diagnosed with AML receiving the combination of the drugs; Arm B has subjects who are have relapsed/refractory AML and HMA failure MDS patients being allocated to either the combination Arm B or single agent AZD1775 Arm C.
Timeline
- Start
- 2019-05-08
- Primary completion
- 2019-09-27
- Completion
- 2019-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | — | — |
| Subject | Cytarabine | Small molecule | — | — |